Field-Initiated Buprenorphine: 2026 EMS Guide
Naloxone reverses the overdose. Then what?
For decades, that question had one answer: load and go. Run another call. See the same patient next week, or read their name in the medical examiner’s report. The cycle was brutal and predictable, and most EMS crews accepted it as part of the job.
That’s changing fast. Field-initiated buprenorphine is now a recognized prehospital intervention, and it’s spreading quickly across U.S. EMS systems. In March 2026, Cooper EMS in Camden, New Jersey became the first agency in the country to put long-acting injectable buprenorphine on their ambulances. A single field dose delivers one week to one month of opioid use disorder coverage from one EMS encounter. The 2026 ESO EMS Index confirmed documented prehospital buprenorphine administrations more than doubled between 2023 and 2025 nationwide.
Field-initiated buprenorphine is no longer experimental. Every EMS provider should understand what it is, why it works, and where it’s heading.
What Field-Initiated Buprenorphine Actually Is
Buprenorphine is a partial opioid agonist that binds tightly to opioid receptors without producing the full agonist effect of heroin, fentanyl, or oxycodone. It stops withdrawal symptoms within minutes, blunts cravings, and reduces the risk of repeat overdose. Unlike naloxone, which is a rescue medication, buprenorphine is a treatment medication.
The original field-initiated buprenorphine protocols used sublingual film. A paramedic would assess a patient who had just been reversed with naloxone, confirm moderate to severe withdrawal using the Clinical Opioid Withdrawal Scale (COWS), and administer a starting dose under the tongue. Cooper EMS pioneered this in 2019 with their Bupe FIRST program.
The 2026 evolution is the extended-release injectable. One subcutaneous shot. Up to a month of coverage. The patient gets a treatment runway that doesn’t depend on showing up to a clinic the next morning or remembering an appointment while in active withdrawal.
Why the Evidence Behind Field-Initiated Buprenorphine Is Hard to Argue With
A peer-reviewed study in Annals of Emergency Medicine found that patients who received buprenorphine from EMS after an overdose reversal were six times more likely to be in long-term addiction treatment 30 days later. The first-year pilot from Alameda County showed 50 percent treatment retention at seven days and 36 percent at 30 days, with zero adverse outcomes across 36 patients.
For a population that historically refuses transport, skips follow-up, and dies at staggering rates, those numbers represent a different category of outcome.
Field-Initiated Buprenorphine and Your Scope of Practice
Field-initiated buprenorphine is authorized in a growing list of states including Washington, New Jersey, California, and others, but rollout is uneven. Some states have added it to the approved paramedic skills list. Others run pilot programs with specific agencies.
A few things worth knowing right now:
Buprenorphine requires patient assessment for active withdrawal. Giving it to a patient who still has full opioid agonists on board causes precipitated withdrawal, which is significantly worse than the withdrawal you’re trying to treat. The COWS score is the standard assessment tool, and most field-initiated buprenorphine protocols require a minimum score before administration.
Current protocols typically require online medical control consultation before administration, especially for the injectable form. This is not a freelance skill.
Patient connection to follow-up care is part of the protocol, not a nice-to-have. Successful programs partner with substance use navigators, peer recovery specialists, or local treatment centers before they push a single dose.
Where Field-Initiated Buprenorphine Is Heading
The injectable form will spread faster than the sublingual did. The operational pitch is too clean: one encounter, one month of coverage, dramatically improved odds of long-term recovery. Community paramedicine programs will absorb a large share of follow-up work, including second injections and warm handoffs to outpatient care.
The providers who shape the next decade of EMS will be the ones who treat opioid use disorder as a treatable medical condition. The clinical case for field-initiated buprenorphine is settled. The cultural shift is still in progress.
If you’ve spent time on the back of a truck running overdose calls, you already know the patients we’re talking about. Field-initiated buprenorphine is the first intervention in a long time that gives EMS a real shot at changing the outcome for those patients. Worth knowing inside and out.
Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice, clinical guidance, or protocol authorization. Scope of practice, medication administration, and field protocols vary by state, region, and agency. EMS providers must follow the protocols established by their state EMS office, local medical director, and employing agency. Always consult your medical director and current local protocols before administering any medication or implementing any clinical intervention discussed in this article. CE Solutions is not affiliated with Cooper EMS, ESO Index, or any agencies or studies referenced.
